Bolt Biotherapeutics (BOLT) Competitors

Bolt Biotherapeutics (NASDAQ:BOLT) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.

Is BOLT or FBIO more profitable?

Fortress Biotech has a net margin of -84.53% compared to Bolt Biotherapeutics' net margin of -665.56%. Fortress Biotech's return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-665.56%	-69.46%	-48.55%
Fortress Biotech	-84.53%	N/A	-34.93%

Do institutionals & insiders have more ownership in BOLT or FBIO?

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 30.9% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer BOLT or FBIO?

Fortress Biotech received 248 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 63.69% of users gave Fortress Biotech an outperform vote while only 63.49% of users gave Bolt Biotherapeutics an outperform vote.

Company	Underperform	Outperform
Bolt Biotherapeutics	Outperform Votes 80 63.49%	Underperform Votes 46 36.51%
Fortress Biotech	Outperform Votes 328 63.69%	Underperform Votes 187 36.31%

Which has higher earnings and valuation, BOLT or FBIO?

Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Fortress Biotech is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.69M	1.75	-$69.20M	-$1.66	-0.21
Fortress Biotech	$57.68M	0.90	-$60.64M	-$2.78	-0.63

Does the media prefer BOLT or FBIO?

In the previous week, Bolt Biotherapeutics had 3 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Bolt Biotherapeutics and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.87 beat Bolt Biotherapeutics' score of 0.51 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Positive
Fortress Biotech	Very Positive

Do analysts prefer BOLT or FBIO?

Bolt Biotherapeutics presently has a consensus price target of $1.13, suggesting a potential upside of 220.51%. Fortress Biotech has a consensus price target of $21.00, suggesting a potential upside of 1,100.00%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, BOLT or FBIO?

Bolt Biotherapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Summary

Fortress Biotech beats Bolt Biotherapeutics on 14 of the 18 factors compared between the two stocks.